Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 75 | 2024 | 16764 | 1.690 |
Why?
|
Antiretroviral Therapy, Highly Active | 16 | 2020 | 1896 | 1.540 |
Why?
|
Anti-HIV Agents | 41 | 2020 | 4320 | 1.440 |
Why?
|
Acquired Immunodeficiency Syndrome | 17 | 2015 | 2241 | 1.110 |
Why?
|
HIV-1 | 31 | 2021 | 6931 | 1.060 |
Why?
|
Anti-Retroviral Agents | 12 | 2020 | 1734 | 0.980 |
Why?
|
Paraparesis, Tropical Spastic | 1 | 2023 | 32 | 0.940 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2023 | 140 | 0.890 |
Why?
|
Viral Load | 23 | 2023 | 3299 | 0.830 |
Why?
|
Peripheral Nervous System Diseases | 6 | 2020 | 703 | 0.780 |
Why?
|
Hepatitis C, Chronic | 6 | 2023 | 1026 | 0.720 |
Why?
|
Exanthema | 1 | 2023 | 491 | 0.670 |
Why?
|
CD4 Lymphocyte Count | 20 | 2021 | 2602 | 0.660 |
Why?
|
Hepatitis C | 9 | 2023 | 1580 | 0.640 |
Why?
|
Benzoxazines | 12 | 2015 | 306 | 0.590 |
Why?
|
Reverse Transcriptase Inhibitors | 9 | 2013 | 624 | 0.560 |
Why?
|
Telephone | 3 | 2013 | 617 | 0.440 |
Why?
|
Iron | 1 | 2020 | 1776 | 0.420 |
Why?
|
Hepacivirus | 10 | 2023 | 1371 | 0.410 |
Why?
|
Tenosynovitis | 1 | 2011 | 57 | 0.400 |
Why?
|
Nelfinavir | 8 | 2011 | 68 | 0.400 |
Why?
|
Syphilis | 2 | 2010 | 225 | 0.390 |
Why?
|
Herpes Zoster | 2 | 2014 | 267 | 0.370 |
Why?
|
Eye Infections | 1 | 2010 | 63 | 0.360 |
Why?
|
Medication Adherence | 8 | 2016 | 2047 | 0.360 |
Why?
|
Arteritis | 2 | 2024 | 159 | 0.320 |
Why?
|
Proguanil | 1 | 2007 | 11 | 0.320 |
Why?
|
Atovaquone | 1 | 2007 | 58 | 0.310 |
Why?
|
Treatment Failure | 9 | 2016 | 2614 | 0.310 |
Why?
|
Babesia microti | 1 | 2007 | 31 | 0.310 |
Why?
|
Oxazines | 6 | 2006 | 302 | 0.310 |
Why?
|
Patient Compliance | 4 | 2013 | 2679 | 0.300 |
Why?
|
Genetic Variation | 3 | 2020 | 6539 | 0.300 |
Why?
|
Stavudine | 5 | 2014 | 86 | 0.290 |
Why?
|
Body Image | 3 | 2020 | 608 | 0.290 |
Why?
|
Babesiosis | 1 | 2007 | 90 | 0.290 |
Why?
|
Alkynes | 12 | 2015 | 310 | 0.270 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 4 | 2020 | 138 | 0.270 |
Why?
|
Zidovudine | 6 | 2014 | 623 | 0.270 |
Why?
|
HIV | 6 | 2023 | 1607 | 0.270 |
Why?
|
Interferon-alpha | 5 | 2013 | 895 | 0.260 |
Why?
|
Cyclopropanes | 12 | 2015 | 421 | 0.260 |
Why?
|
Lamivudine | 5 | 2014 | 342 | 0.260 |
Why?
|
Antiviral Agents | 6 | 2023 | 2971 | 0.260 |
Why?
|
Hemochromatosis | 3 | 2020 | 184 | 0.260 |
Why?
|
Immunocompromised Host | 2 | 2019 | 845 | 0.240 |
Why?
|
Adult | 66 | 2023 | 213394 | 0.240 |
Why?
|
DNA, Mitochondrial | 4 | 2012 | 804 | 0.240 |
Why?
|
Nurses | 1 | 2013 | 2455 | 0.230 |
Why?
|
CD4-Positive T-Lymphocytes | 10 | 2011 | 4374 | 0.230 |
Why?
|
T-Lymphocytes, Helper-Inducer | 5 | 2003 | 986 | 0.230 |
Why?
|
Decision Support Systems, Clinical | 1 | 2012 | 1162 | 0.230 |
Why?
|
RNA, Viral | 14 | 2012 | 2907 | 0.230 |
Why?
|
Drug Resistance, Viral | 5 | 2016 | 829 | 0.220 |
Why?
|
Abdominal Pain | 2 | 2019 | 1053 | 0.210 |
Why?
|
Female | 70 | 2024 | 378853 | 0.210 |
Why?
|
Male | 72 | 2024 | 349022 | 0.210 |
Why?
|
Humans | 113 | 2024 | 739398 | 0.210 |
Why?
|
Lymphoproliferative Disorders | 1 | 2005 | 525 | 0.200 |
Why?
|
Middle Aged | 50 | 2024 | 212863 | 0.200 |
Why?
|
Oxidoreductases, N-Demethylating | 2 | 2012 | 114 | 0.200 |
Why?
|
Genotype | 8 | 2023 | 12951 | 0.190 |
Why?
|
HIV-2 | 1 | 2021 | 171 | 0.190 |
Why?
|
AIDS-Related Opportunistic Infections | 3 | 2014 | 664 | 0.190 |
Why?
|
T-Lymphocyte Subsets | 1 | 2009 | 1834 | 0.190 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 2 | 2012 | 257 | 0.190 |
Why?
|
Spironolactone | 1 | 2023 | 378 | 0.180 |
Why?
|
Travel | 2 | 2017 | 787 | 0.180 |
Why?
|
AIDS Vaccines | 2 | 2004 | 924 | 0.180 |
Why?
|
Tuberculosis, Gastrointestinal | 1 | 2019 | 20 | 0.180 |
Why?
|
Pharyngitis | 1 | 2021 | 214 | 0.180 |
Why?
|
CD8-Positive T-Lymphocytes | 11 | 2010 | 4424 | 0.170 |
Why?
|
Confusion | 1 | 2021 | 271 | 0.170 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2005 | 566 | 0.170 |
Why?
|
Diagnosis, Differential | 8 | 2021 | 12948 | 0.170 |
Why?
|
Drug Therapy, Combination | 13 | 2015 | 6478 | 0.170 |
Why?
|
HLA-B Antigens | 2 | 2010 | 352 | 0.170 |
Why?
|
Lymphopenia | 1 | 2021 | 286 | 0.170 |
Why?
|
Receptors, Transferrin | 1 | 2020 | 297 | 0.170 |
Why?
|
Didanosine | 4 | 2007 | 153 | 0.170 |
Why?
|
Strongylida Infections | 1 | 2018 | 46 | 0.160 |
Why?
|
Fever | 3 | 2021 | 1607 | 0.160 |
Why?
|
Elasticity Imaging Techniques | 1 | 2023 | 385 | 0.160 |
Why?
|
Ferritins | 1 | 2020 | 589 | 0.150 |
Why?
|
Polyethylene Glycols | 3 | 2009 | 1182 | 0.150 |
Why?
|
Dideoxynucleosides | 2 | 2015 | 124 | 0.150 |
Why?
|
Treatment Outcome | 17 | 2024 | 62693 | 0.140 |
Why?
|
Radio Frequency Identification Device | 1 | 2015 | 21 | 0.140 |
Why?
|
Standard of Care | 2 | 2016 | 563 | 0.130 |
Why?
|
Heterozygote | 2 | 2020 | 2798 | 0.130 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2003 | 1822 | 0.130 |
Why?
|
HIV Antibodies | 1 | 2021 | 1309 | 0.120 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 5702 | 0.120 |
Why?
|
Neuralgia | 1 | 2020 | 565 | 0.120 |
Why?
|
Atherosclerosis | 2 | 2024 | 3401 | 0.120 |
Why?
|
CD4-CD8 Ratio | 2 | 2012 | 112 | 0.110 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2013 | 248 | 0.110 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2014 | 244 | 0.110 |
Why?
|
Encephalitis, Viral | 1 | 2013 | 55 | 0.110 |
Why?
|
Rabies | 1 | 2013 | 59 | 0.110 |
Why?
|
Appointments and Schedules | 2 | 2014 | 415 | 0.110 |
Why?
|
Reminder Systems | 2 | 2012 | 370 | 0.110 |
Why?
|
Sweet Syndrome | 1 | 2012 | 47 | 0.110 |
Why?
|
Bisexuality | 1 | 2014 | 269 | 0.110 |
Why?
|
Aging | 2 | 2022 | 8613 | 0.100 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2012 | 53 | 0.100 |
Why?
|
Lymphocyte Activation | 5 | 2012 | 5522 | 0.100 |
Why?
|
Viremia | 5 | 2007 | 733 | 0.100 |
Why?
|
Self Care | 2 | 2014 | 787 | 0.100 |
Why?
|
Genome, Mitochondrial | 1 | 2011 | 71 | 0.100 |
Why?
|
Abdominal Wall | 1 | 2012 | 155 | 0.100 |
Why?
|
HIV Reverse Transcriptase | 1 | 2012 | 215 | 0.100 |
Why?
|
Amino Acids | 2 | 2015 | 1727 | 0.100 |
Why?
|
Seasons | 1 | 2017 | 1486 | 0.100 |
Why?
|
Cholesterol, HDL | 1 | 2017 | 1807 | 0.100 |
Why?
|
Lipid Metabolism | 2 | 2017 | 1891 | 0.100 |
Why?
|
Cardiolipins | 1 | 2010 | 88 | 0.090 |
Why?
|
Erythema | 1 | 2011 | 254 | 0.090 |
Why?
|
Colon | 1 | 2018 | 1771 | 0.090 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2010 | 115 | 0.090 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2015 | 428 | 0.090 |
Why?
|
Genes, MHC Class I | 1 | 2010 | 257 | 0.090 |
Why?
|
Nucleosides | 2 | 2012 | 138 | 0.090 |
Why?
|
HIV Protease Inhibitors | 2 | 2009 | 435 | 0.090 |
Why?
|
Massachusetts | 3 | 2012 | 8669 | 0.090 |
Why?
|
Double-Blind Method | 8 | 2015 | 11985 | 0.090 |
Why?
|
Time Factors | 9 | 2016 | 40050 | 0.090 |
Why?
|
Biosensing Techniques | 1 | 2015 | 665 | 0.090 |
Why?
|
Smoking Cessation | 1 | 2021 | 2067 | 0.080 |
Why?
|
Phosphatidylcholines | 1 | 2010 | 412 | 0.080 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2009 | 103 | 0.080 |
Why?
|
Truth Disclosure | 1 | 2012 | 437 | 0.080 |
Why?
|
HIV Seropositivity | 2 | 2012 | 966 | 0.080 |
Why?
|
Sexual Partners | 1 | 2012 | 727 | 0.080 |
Why?
|
Dementia | 1 | 2022 | 2488 | 0.080 |
Why?
|
Epistasis, Genetic | 1 | 2011 | 365 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1911 | 0.080 |
Why?
|
Toll-Like Receptor 7 | 1 | 2009 | 172 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2014 | 3908 | 0.080 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2003 | 1369 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2010 | 592 | 0.080 |
Why?
|
Adipose Tissue | 4 | 2020 | 3280 | 0.080 |
Why?
|
Health Behavior | 2 | 2022 | 2624 | 0.080 |
Why?
|
Eye Infections, Bacterial | 1 | 2010 | 236 | 0.080 |
Why?
|
Cerebrospinal Fluid | 1 | 2010 | 536 | 0.070 |
Why?
|
Drug Combinations | 2 | 2014 | 1959 | 0.070 |
Why?
|
GB virus C | 1 | 2006 | 9 | 0.070 |
Why?
|
Minority Groups | 1 | 2014 | 1197 | 0.070 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2009 | 253 | 0.070 |
Why?
|
Immunity, Cellular | 2 | 2004 | 1603 | 0.070 |
Why?
|
Quality of Life | 4 | 2023 | 12640 | 0.070 |
Why?
|
Sexual Behavior | 2 | 2014 | 2040 | 0.070 |
Why?
|
Leukocyte Count | 1 | 2010 | 1581 | 0.070 |
Why?
|
Social Stigma | 1 | 2012 | 695 | 0.070 |
Why?
|
Homosexuality, Male | 1 | 2014 | 1239 | 0.070 |
Why?
|
Proteinuria | 1 | 2009 | 654 | 0.070 |
Why?
|
Dyspnea | 1 | 2014 | 1295 | 0.070 |
Why?
|
Creatinine | 2 | 2009 | 1903 | 0.070 |
Why?
|
Ambulatory Care Facilities | 1 | 2012 | 928 | 0.070 |
Why?
|
Crohn Disease | 1 | 2019 | 2299 | 0.070 |
Why?
|
Aged | 19 | 2022 | 162698 | 0.070 |
Why?
|
T-Lymphocytes | 3 | 2013 | 10142 | 0.070 |
Why?
|
Ribavirin | 2 | 2007 | 395 | 0.070 |
Why?
|
Liver | 2 | 2023 | 7449 | 0.070 |
Why?
|
Cardiovascular Diseases | 3 | 2022 | 15070 | 0.070 |
Why?
|
Virus Integration | 1 | 2008 | 297 | 0.070 |
Why?
|
Depression | 4 | 2021 | 7689 | 0.070 |
Why?
|
Hepatitis, Viral, Human | 1 | 2006 | 137 | 0.070 |
Why?
|
Health Literacy | 1 | 2011 | 413 | 0.070 |
Why?
|
Epitopes, T-Lymphocyte | 4 | 2004 | 877 | 0.070 |
Why?
|
Plasmodium falciparum | 1 | 2015 | 1730 | 0.070 |
Why?
|
Drug Monitoring | 1 | 2012 | 961 | 0.070 |
Why?
|
Malaria | 1 | 2015 | 1234 | 0.070 |
Why?
|
Anxiety | 4 | 2022 | 4253 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2021 | 9812 | 0.060 |
Why?
|
Antigen Presentation | 1 | 2010 | 1286 | 0.060 |
Why?
|
Risk Factors | 8 | 2022 | 71974 | 0.060 |
Why?
|
Genome-Wide Association Study | 5 | 2015 | 12178 | 0.060 |
Why?
|
Intra-Abdominal Fat | 1 | 2009 | 590 | 0.060 |
Why?
|
Haplotypes | 4 | 2012 | 2782 | 0.060 |
Why?
|
Cesarean Section | 1 | 2012 | 1371 | 0.060 |
Why?
|
Young Adult | 9 | 2017 | 56255 | 0.060 |
Why?
|
Patient Education as Topic | 2 | 2011 | 2275 | 0.060 |
Why?
|
Medical Records Systems, Computerized | 1 | 2010 | 1205 | 0.060 |
Why?
|
Adaptation, Psychological | 1 | 2014 | 2564 | 0.060 |
Why?
|
Chronic Disease | 4 | 2011 | 9133 | 0.060 |
Why?
|
Coronary Vessels | 1 | 2015 | 3097 | 0.060 |
Why?
|
Social Support | 3 | 2022 | 2112 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 6 | 2015 | 15500 | 0.060 |
Why?
|
Brain | 3 | 2021 | 26345 | 0.060 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15511 | 0.060 |
Why?
|
Receptors, Mineralocorticoid | 1 | 2024 | 164 | 0.050 |
Why?
|
Boston | 3 | 2012 | 9314 | 0.050 |
Why?
|
Dendritic Cells | 2 | 2013 | 2728 | 0.050 |
Why?
|
Cystitis | 1 | 2002 | 92 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6516 | 0.050 |
Why?
|
HLA-DR Antigens | 1 | 2003 | 643 | 0.050 |
Why?
|
Gene Products, rev | 1 | 2001 | 31 | 0.050 |
Why?
|
BK Virus | 1 | 2002 | 129 | 0.050 |
Why?
|
Cholesterol | 1 | 2010 | 2900 | 0.050 |
Why?
|
Albuminuria | 1 | 2005 | 692 | 0.050 |
Why?
|
DNA, Viral | 1 | 2008 | 2223 | 0.050 |
Why?
|
Colonoscopy | 2 | 2019 | 1363 | 0.050 |
Why?
|
Gene Products, tat | 1 | 2001 | 120 | 0.050 |
Why?
|
Virus Replication | 1 | 2009 | 2529 | 0.050 |
Why?
|
Absorptiometry, Photon | 4 | 2008 | 1726 | 0.050 |
Why?
|
Hepatitis C Antigens | 1 | 2000 | 34 | 0.050 |
Why?
|
HLA-A2 Antigen | 1 | 2001 | 213 | 0.050 |
Why?
|
Immunologic Memory | 2 | 2006 | 1348 | 0.050 |
Why?
|
Data Collection | 1 | 2010 | 3341 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2010 | 3194 | 0.050 |
Why?
|
Self Efficacy | 1 | 2004 | 607 | 0.050 |
Why?
|
Herpesvirus 4, Human | 1 | 2005 | 1038 | 0.050 |
Why?
|
Inflammation | 2 | 2017 | 10534 | 0.040 |
Why?
|
Lung | 2 | 2019 | 9782 | 0.040 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2006 | 1359 | 0.040 |
Why?
|
Killer Cells, Natural | 1 | 2009 | 2133 | 0.040 |
Why?
|
Intestine, Large | 1 | 2019 | 71 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 35326 | 0.040 |
Why?
|
Longitudinal Studies | 5 | 2007 | 13880 | 0.040 |
Why?
|
Polymorphism, Genetic | 4 | 2014 | 4332 | 0.040 |
Why?
|
Perfusion | 1 | 2023 | 1354 | 0.040 |
Why?
|
Sex Characteristics | 1 | 2009 | 2583 | 0.040 |
Why?
|
Sickness Impact Profile | 1 | 2020 | 305 | 0.040 |
Why?
|
Decision Making | 1 | 2012 | 3854 | 0.040 |
Why?
|
Case-Control Studies | 6 | 2017 | 21694 | 0.040 |
Why?
|
Cecum | 1 | 2019 | 237 | 0.040 |
Why?
|
Urban Population | 1 | 2007 | 2014 | 0.040 |
Why?
|
Immunization | 1 | 2003 | 1255 | 0.040 |
Why?
|
Epitopes | 4 | 2010 | 2558 | 0.040 |
Why?
|
Parasitic Diseases | 1 | 2018 | 76 | 0.040 |
Why?
|
Liver Diseases | 1 | 2006 | 1244 | 0.040 |
Why?
|
Predictive Value of Tests | 2 | 2021 | 15036 | 0.040 |
Why?
|
Hydrocarbons, Fluorinated | 1 | 2017 | 39 | 0.040 |
Why?
|
Body Composition | 1 | 2007 | 2397 | 0.040 |
Why?
|
Mutation | 4 | 2012 | 29658 | 0.040 |
Why?
|
Prognosis | 3 | 2021 | 28901 | 0.040 |
Why?
|
RNA, Messenger | 1 | 2012 | 13002 | 0.040 |
Why?
|
Acute Disease | 6 | 2006 | 7128 | 0.040 |
Why?
|
Americas | 1 | 2017 | 111 | 0.040 |
Why?
|
Glucose | 1 | 2009 | 4377 | 0.040 |
Why?
|
Protease Inhibitors | 1 | 2001 | 792 | 0.040 |
Why?
|
Testosterone | 1 | 2007 | 2391 | 0.040 |
Why?
|
Substance-Related Disorders | 1 | 2012 | 4239 | 0.030 |
Why?
|
Pilot Projects | 3 | 2022 | 8275 | 0.030 |
Why?
|
United States | 8 | 2022 | 69573 | 0.030 |
Why?
|
Cytarabine | 2 | 1988 | 685 | 0.030 |
Why?
|
Health Personnel | 1 | 2009 | 3203 | 0.030 |
Why?
|
Fibrosis | 1 | 2023 | 2024 | 0.030 |
Why?
|
Family Practice | 1 | 1999 | 516 | 0.030 |
Why?
|
Containment of Biohazards | 1 | 2015 | 37 | 0.030 |
Why?
|
B-Lymphocytes | 1 | 2009 | 4663 | 0.030 |
Why?
|
Liberia | 1 | 2015 | 167 | 0.030 |
Why?
|
Radiography, Abdominal | 1 | 2018 | 535 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2006 | 3087 | 0.030 |
Why?
|
Interferon-gamma | 4 | 2006 | 3193 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2024 | 2026 | 0.030 |
Why?
|
Attitude to Health | 1 | 2004 | 2047 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 12049 | 0.030 |
Why?
|
Zimbabwe | 1 | 2014 | 130 | 0.030 |
Why?
|
Clinical Trials as Topic | 3 | 2006 | 7897 | 0.030 |
Why?
|
Natural Language Processing | 1 | 2022 | 1024 | 0.030 |
Why?
|
Gene Frequency | 2 | 2012 | 3585 | 0.030 |
Why?
|
Eosinophilia | 1 | 2018 | 531 | 0.030 |
Why?
|
Fear | 1 | 2022 | 1430 | 0.030 |
Why?
|
Gelatin | 1 | 2015 | 226 | 0.030 |
Why?
|
Pharmacogenetics | 2 | 2010 | 679 | 0.030 |
Why?
|
Multicenter Studies as Topic | 2 | 2014 | 1583 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2009 | 4920 | 0.030 |
Why?
|
Recombinant Proteins | 3 | 2009 | 6610 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1469 | 0.030 |
Why?
|
Biological Transport | 1 | 2017 | 2118 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3526 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2023 | 1838 | 0.030 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1262 | 0.030 |
Why?
|
Haiti | 1 | 2014 | 550 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2017 | 19220 | 0.030 |
Why?
|
Immunity, Innate | 2 | 2017 | 2950 | 0.030 |
Why?
|
Adolescent | 9 | 2016 | 85405 | 0.030 |
Why?
|
Hepatitis C Antibodies | 2 | 2004 | 145 | 0.030 |
Why?
|
Triglycerides | 1 | 2020 | 2447 | 0.030 |
Why?
|
Molecular Sequence Data | 4 | 2011 | 18125 | 0.030 |
Why?
|
Retrospective Studies | 4 | 2014 | 76631 | 0.030 |
Why?
|
Bites and Stings | 1 | 2013 | 90 | 0.030 |
Why?
|
Condoms | 1 | 2014 | 321 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2010 | 7136 | 0.030 |
Why?
|
Chiroptera | 1 | 2013 | 104 | 0.030 |
Why?
|
Electrical Equipment and Supplies | 1 | 2012 | 27 | 0.030 |
Why?
|
Thymidine | 1 | 2012 | 317 | 0.030 |
Why?
|
Menopause | 1 | 2020 | 1613 | 0.030 |
Why?
|
Paresthesia | 1 | 2013 | 159 | 0.030 |
Why?
|
San Francisco | 1 | 2012 | 159 | 0.030 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 24714 | 0.030 |
Why?
|
Peru | 1 | 2014 | 879 | 0.030 |
Why?
|
Substance Abuse, Intravenous | 1 | 2016 | 523 | 0.030 |
Why?
|
Botswana | 1 | 2014 | 1034 | 0.020 |
Why?
|
Health Care Surveys | 1 | 1999 | 2448 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 2012 | 382 | 0.020 |
Why?
|
Blood Glucose | 1 | 2005 | 6237 | 0.020 |
Why?
|
Receptors, Drug | 1 | 2011 | 161 | 0.020 |
Why?
|
History, 21st Century | 1 | 2017 | 1534 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2014 | 937 | 0.020 |
Why?
|
Loneliness | 1 | 2012 | 181 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 146 | 0.020 |
Why?
|
Brazil | 1 | 2014 | 1264 | 0.020 |
Why?
|
Hemorrhage | 1 | 2002 | 3441 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 228 | 0.020 |
Why?
|
Anticholesteremic Agents | 1 | 2017 | 979 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2012 | 15194 | 0.020 |
Why?
|
Phospholipases A | 1 | 1990 | 216 | 0.020 |
Why?
|
HIV Long-Term Survivors | 1 | 2010 | 126 | 0.020 |
Why?
|
Potassium Channels, Inwardly Rectifying | 1 | 2011 | 150 | 0.020 |
Why?
|
Uganda | 1 | 2014 | 1230 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 1689 | 0.020 |
Why?
|
Shock | 1 | 2012 | 318 | 0.020 |
Why?
|
Models, Psychological | 1 | 2014 | 809 | 0.020 |
Why?
|
Sequence Analysis, DNA | 2 | 2012 | 4791 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2020 | 3757 | 0.020 |
Why?
|
Oligopeptides | 2 | 2009 | 1179 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2022 | 19811 | 0.020 |
Why?
|
Blood-Borne Pathogens | 1 | 2009 | 52 | 0.020 |
Why?
|
HIV Antigens | 1 | 2010 | 343 | 0.020 |
Why?
|
Research Personnel | 1 | 2014 | 571 | 0.020 |
Why?
|
Kinetics | 2 | 2008 | 6475 | 0.020 |
Why?
|
Prospective Studies | 5 | 2021 | 53037 | 0.020 |
Why?
|
Needlestick Injuries | 1 | 2009 | 68 | 0.020 |
Why?
|
South Africa | 1 | 2014 | 1743 | 0.020 |
Why?
|
Life Style | 1 | 2021 | 3817 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2006 | 7862 | 0.020 |
Why?
|
Pulmonary Emphysema | 1 | 2014 | 670 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 2946 | 0.020 |
Why?
|
Risk-Taking | 1 | 2014 | 986 | 0.020 |
Why?
|
Disease Progression | 3 | 2010 | 13237 | 0.020 |
Why?
|
Counseling | 1 | 2016 | 1526 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2021 | 3609 | 0.020 |
Why?
|
Necrosis | 1 | 2012 | 1643 | 0.020 |
Why?
|
Drosophila Proteins | 1 | 2017 | 1697 | 0.020 |
Why?
|
Sulfonamides | 1 | 2017 | 1934 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2013 | 1850 | 0.020 |
Why?
|
Critical Illness | 1 | 2021 | 2656 | 0.020 |
Why?
|
Prevalence | 2 | 2020 | 15153 | 0.020 |
Why?
|
Headache | 1 | 2015 | 1199 | 0.020 |
Why?
|
Nurse-Patient Relations | 1 | 2008 | 101 | 0.020 |
Why?
|
Algorithms | 2 | 2022 | 13872 | 0.020 |
Why?
|
Ritonavir | 1 | 2009 | 324 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2013 | 1866 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 562 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3672 | 0.020 |
Why?
|
Malaria, Falciparum | 1 | 2015 | 1066 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2013 | 607 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2009 | 371 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3510 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2012 | 1453 | 0.020 |
Why?
|
HIV Core Protein p24 | 1 | 2006 | 256 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 2018 | 2530 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2881 | 0.020 |
Why?
|
Adenine | 1 | 2012 | 940 | 0.020 |
Why?
|
Amino Acid Sequence | 3 | 2004 | 13816 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2014 | 2303 | 0.020 |
Why?
|
Electroencephalography | 1 | 2021 | 6133 | 0.020 |
Why?
|
Lung Diseases, Interstitial | 1 | 2014 | 804 | 0.020 |
Why?
|
Tuberculosis | 1 | 2018 | 1892 | 0.020 |
Why?
|
Animals | 4 | 2017 | 168368 | 0.020 |
Why?
|
Base Sequence | 2 | 2011 | 12804 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 20055 | 0.020 |
Why?
|
Electronic Health Records | 1 | 2022 | 4426 | 0.020 |
Why?
|
Sleep | 1 | 2021 | 4596 | 0.020 |
Why?
|
Comorbidity | 2 | 2012 | 10362 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2021 | 14740 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2015 | 2334 | 0.020 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2017 | 2028 | 0.020 |
Why?
|
Interpersonal Relations | 1 | 2012 | 1421 | 0.020 |
Why?
|
Cognition | 1 | 2022 | 6686 | 0.020 |
Why?
|
Progesterone | 1 | 2009 | 772 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2007 | 888 | 0.020 |
Why?
|
Exercise | 1 | 2021 | 5591 | 0.020 |
Why?
|
Lymphocyte Count | 1 | 2006 | 791 | 0.020 |
Why?
|
Medicare | 1 | 2022 | 6497 | 0.020 |
Why?
|
Remission, Spontaneous | 1 | 2004 | 377 | 0.010 |
Why?
|
Qualitative Research | 1 | 2012 | 2656 | 0.010 |
Why?
|
California | 1 | 2008 | 1400 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5462 | 0.010 |
Why?
|
Placenta | 1 | 2012 | 1682 | 0.010 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2005 | 419 | 0.010 |
Why?
|
Plaque, Atherosclerotic | 1 | 2015 | 1483 | 0.010 |
Why?
|
Body Size | 1 | 2006 | 458 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2694 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 2007 | 496 | 0.010 |
Why?
|
Radiography | 1 | 2014 | 6998 | 0.010 |
Why?
|
Pregnancy | 2 | 2017 | 29002 | 0.010 |
Why?
|
Immunoassay | 1 | 2006 | 750 | 0.010 |
Why?
|
Interferons | 1 | 2006 | 703 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8274 | 0.010 |
Why?
|
Protein Conformation | 1 | 2010 | 4012 | 0.010 |
Why?
|
Body Mass Index | 1 | 2020 | 12655 | 0.010 |
Why?
|
Genes, MHC Class II | 1 | 2003 | 458 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 1988 | 3485 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5948 | 0.010 |
Why?
|
Age Factors | 2 | 2012 | 18349 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2012 | 5058 | 0.010 |
Why?
|
rev Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 28 | 0.010 |
Why?
|
Gene Products, vpr | 1 | 2001 | 36 | 0.010 |
Why?
|
vpr Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 39 | 0.010 |
Why?
|
Demography | 1 | 2006 | 1650 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10208 | 0.010 |
Why?
|
Cohort Studies | 3 | 2010 | 40389 | 0.010 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2001 | 126 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5460 | 0.010 |
Why?
|
Polyomavirus Infections | 1 | 2002 | 196 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 3 | 2006 | 17384 | 0.010 |
Why?
|
Peptides | 2 | 2003 | 4395 | 0.010 |
Why?
|
Gene Products, gag | 1 | 2000 | 337 | 0.010 |
Why?
|
Tumor Virus Infections | 1 | 2002 | 452 | 0.010 |
Why?
|
Genome, Human | 1 | 2012 | 4419 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6942 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2009 | 1791 | 0.010 |
Why?
|
Italy | 1 | 2001 | 827 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1990 | 4400 | 0.010 |
Why?
|
HLA Antigens | 1 | 2004 | 1382 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4743 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12237 | 0.010 |
Why?
|
Computational Biology | 1 | 2011 | 3506 | 0.010 |
Why?
|
Dyslipidemias | 1 | 2005 | 851 | 0.010 |
Why?
|
Transcription Factors | 1 | 2017 | 12120 | 0.010 |
Why?
|
Pyridines | 1 | 2009 | 2810 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2004 | 1883 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9387 | 0.010 |
Why?
|
Viral Vaccines | 1 | 2002 | 631 | 0.010 |
Why?
|
Software | 1 | 2011 | 4423 | 0.010 |
Why?
|
DNA Primers | 1 | 2001 | 2893 | 0.010 |
Why?
|
Models, Genetic | 1 | 2006 | 3493 | 0.010 |
Why?
|
Regression Analysis | 1 | 2006 | 6452 | 0.010 |
Why?
|
Viral Proteins | 1 | 2003 | 1900 | 0.010 |
Why?
|
Genomics | 1 | 2012 | 5652 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2006 | 5959 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13402 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2004 | 6370 | 0.010 |
Why?
|
Body Weight | 1 | 2006 | 4660 | 0.010 |
Why?
|
Recurrence | 1 | 2006 | 8307 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2002 | 1377 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2001 | 1269 | 0.010 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2003 | 2517 | 0.010 |
Why?
|
Lipids | 1 | 2005 | 3307 | 0.010 |
Why?
|
Phenotype | 1 | 2012 | 16301 | 0.010 |
Why?
|
DNA | 1 | 1987 | 7275 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7274 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2011 | 5272 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2000 | 4935 | 0.010 |
Why?
|
Binding Sites | 1 | 2001 | 6113 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2005 | 3858 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2013 | 38942 | 0.010 |
Why?
|
Quinacrine | 1 | 1990 | 25 | 0.010 |
Why?
|
Cell Line | 2 | 2001 | 15987 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2006 | 12328 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 1990 | 6310 | 0.010 |
Why?
|
Acetophenones | 1 | 1990 | 48 | 0.010 |
Why?
|
Health Status | 1 | 2004 | 4013 | 0.010 |
Why?
|
Lysophosphatidylcholines | 1 | 1990 | 81 | 0.010 |
Why?
|
Lipoxygenase Inhibitors | 1 | 1990 | 94 | 0.010 |
Why?
|
Phospholipases A2 | 1 | 1990 | 203 | 0.010 |
Why?
|
Inositol Phosphates | 1 | 1990 | 180 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81002 | 0.010 |
Why?
|
Arachidonic Acids | 1 | 1990 | 300 | 0.010 |
Why?
|
Type C Phospholipases | 1 | 1990 | 292 | 0.010 |
Why?
|
Precipitin Tests | 1 | 1990 | 829 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11460 | 0.010 |
Why?
|
Arachidonic Acid | 1 | 1990 | 438 | 0.010 |
Why?
|
Choline | 1 | 1990 | 488 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2004 | 4212 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1990 | 1583 | 0.010 |
Why?
|
Leukemia, Myeloid | 1 | 1990 | 705 | 0.000 |
Why?
|
Radioimmunoassay | 1 | 1987 | 918 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2010 | 57650 | 0.000 |
Why?
|
Enzyme Activation | 1 | 1990 | 3701 | 0.000 |
Why?
|
Child, Preschool | 1 | 2007 | 40802 | 0.000 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 1987 | 1580 | 0.000 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1987 | 2558 | 0.000 |
Why?
|
Child | 1 | 2007 | 77033 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1990 | 8400 | 0.000 |
Why?
|